High-throughput genotyping in metastatic esophageal squamous cell carcinoma identifies phosphoinositide-3-kinase and braf mutations

PLoS ONE

Volumn 7, Issue 8, 2012, Pages

  Maeng, Chi Hoon ^a   Lee, Jeeyun ^a   van Hummelen, Paul ^b   Park, Se Hoon ^a   Palescandolo, Emanuele ^b   Jang, Jiryeon ^a   Park, Ha Young ^a   Kang, So Young ^a   MacConaill, Laura ^b   Kim, Kyoung Mee ^a   Shim, Young Mog ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

^b DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; FLUOROPYRIMIDINE; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM;

ADULT; AGED; ARTICLE; BRAF GENE; CANCER SURVIVAL; CNTNNB1 GENE; EGFR GENE; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GENE IDENTIFICATION; GENE LOCATION; GENE MUTATION; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MLH1 GENE; MUTATIONAL ANALYSIS; ONCOGENE; OVERALL SURVIVAL; PIK3CA GENE; SOMATIC MUTATION; TP53 GENE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; AGED; AMINO ACID SUBSTITUTION; CARCINOMA, SQUAMOUS CELL; DISEASE-FREE SURVIVAL; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM METASTASIS; NUCLEAR PROTEINS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PYRIMIDINES; SURVIVAL RATE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84864554415     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041655     Document Type: Article

References (23)

1. Jemal A, Bray F, ((2011)) Center MM, Ferlay J, Ward E, et al ((2011)) Global cancer statistics. CA Cancer J Clin 61:: 69--90.
2. Gholipour C, Shalchi RA, Abbasi M, ((2008)) A histopathological study of esophageal cancer on the western side of the Caspian littoral from 1994 to 2003. Dis Esophagus 21:: 322--327.
3. Enzinger PC, Mayer RJ, ((2003)) Esophageal cancer. N Engl J Med 349:: 2241--2252.
4. Adenis A, Penel N, Horn S, Dominguez S, Vanhuyse M, et al. ((2010)) Palliative chemotherapy does not improve survival in metastatic esophageal cancer. Oncology 79:: 46--54.
5. Qin TJ, An GL, Zhao XH, Tian F, Li XH, et al. ((2009)) Combined treatment of oxaliplatin and capecitabine in patients with metastatic esophageal squamous cell cancer. World J Gastroenterol 15:: 871--876.
6. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, et al. ((2007)) High-throughput oncogene mutation profiling in human cancer. Nat Genet 39:: 347--351.
7. MacConaill LE, Campbell CD, Kehoe SM, Bass AJ, Hatton C, et al. ((2009)) Profiling critical cancer gene mutations in clinical tumor samples. PLoS One 4:: e7887.
8. Samuels Y, Diaz LA, Schmidt-Kittler O, Cummins JM, DeLong L, et al. ((2005)) Mutant PIK3CA promotes cell growth and invasion of human cancer cells. Cancer Cell 7:: 561--573.
9. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, et al. ((2004)) High frequency of mutations of the PIK3CA gene in human cancers. Science 304:: 554.
10. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, et al. ((2004)) Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64:: 5048--5050.
11. Mao C, Yang ZY, Hu XF, Chen Q, Tang JL, ((2011)) PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol.
12. Campbell IG, Russell SE, Phillips WA, ((2005)) PIK3CA mutations in ovarian cancer. Clin Cancer Res 11: 7042; author reply 7042-7043.
13. Luo J, Manning BD, Cantley LC, ((2003)) Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4:: 257--262.
14. Tanaka H, Yoshida M, Tanimura H, Fujii T, Sakata K, et al. ((2011)) The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations. Clin Cancer Res 17:: 3272--3281.
15. Kong D, Dan S, Yamazaki K, Yamori T, ((2010)) Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur J Cancer 46:: 1111--1121.
16. Mori R, Ishiguro H, Kimura M, Mitsui A, Sasaki H, et al. ((2008)) PIK3CA mutation status in Japanese esophageal squamous cell carcinoma. J Surg Res 145:: 320--326.
17. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. ((2002)) Mutations of the BRAF gene in human cancer. Nature 417:: 949--954.
18. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, et al. ((2010)) Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 467:: 596--599.
19. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, et al. ((2011)) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:: 2507--2516.
20. Goh AM, Coffill CR, Lane DP, ((2011)) The role of mutant p53 in human cancer. J Pathol 223:: 116--126.
21. Rossini A, de Almeida Simao T, Marques CB, Soares-Lima SC, Herbster S, et al. ((2010)) TP53 mutation profile of esophageal squamous cell carcinomas of patients from Southeastern Brazil. Mutat Res 696:: 10--15.
22. Matulonis UA, Hirsch M, Palescandolo E, Kim E, Liu J, et al. ((2011)) High throughput interrogation of somatic mutations in high grade serous cancer of the ovary. PLoS One 6:: e24433.
23. Choy E, Hornicek F, Macconaill L, Harmon D, Tariq Z,et al. High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes. Cancer. In press.